Empagliflozin in Heart Failure with a Preserved Ejection Fraction
2021 · New England Journal of Medicine · 4,374 citations
https://doi.org/10.1056/nejmoa2107038
J
James L. Januzzi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.2K
Papers
99.4K
Citations
134
h-index
665
i10-index
James L. Januzzi is an academic researcher from Harvard University. The author has contributed to research in topics: Heart Failure Treatment and Management & Cardiovascular Function and Risk Factors & Acute Myocardial Infarction Research. The author has an h-index of 134, co-authored 1003 publications.
ORCID: 0000-0002-8338-1798Papers by this author
worksUniversal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
2021 · European Journal of Heart Failure · 1,471 citations
https://doi.org/10.1002/ejhf.2115
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients
2005 · European Heart Journal · 1,134 citations
https://doi.org/10.1093/eurheartj/ehi631
Heart Failure With Reduced Ejection Fraction
2020 · JAMA · 681 citations
https://doi.org/10.1001/jama.2020.10262
Inflammation in Heart Failure
2020 · Journal of the American College of Cardiology · 640 citations
https://doi.org/10.1016/j.jacc.2020.01.014
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association
2017 · Circulation · 567 citations
https://doi.org/10.1161/cir.0000000000000490
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat